Related Experiment Video

Updated: Feb 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping

Yu Zhang1, Jinping Yin1, Feng Peng1

  • 1Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.

Lung Cancer (Amsterdam, Netherlands)
|November 8, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

Potential rules for stable transition metal hexafluorides with high oxidation states under high pressures.

Physical chemistry chemical physics : PCCP·2023

Stable multifunctional aluminum phosphides at high pressures.

Physical chemistry chemical physics : PCCP·2023

A novel visceral adiposity index predicts bone loss in female early rheumatoid arthritis patients detected by HR-pQCT.

Scientific reports·2023

A copper-metal organic framework enhances the photothermal and chemodynamic properties of polydopamine for melanoma therapy.

Acta biomaterialia·2023

A SiO2 layer on PEO-treated Mg for enhanced corrosion resistance and bone regeneration.

Frontiers in bioengineering and biotechnology·2023

Triplex-forming oligonucleotides as an anti-gene technique for cancer therapy.

Frontiers in pharmacology·2023

Lung cytology in the diagnostic workflow: A real-world study of its clinical impact.

Lung cancer (Amsterdam, Netherlands)·2026

Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review.

Lung cancer (Amsterdam, Netherlands)·2026

Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC.

Lung cancer (Amsterdam, Netherlands)·2026

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.

Lung cancer (Amsterdam, Netherlands)·2026

Lung cancer after allogeneic hematopoietic stem cell transplantation.

Lung cancer (Amsterdam, Netherlands)·2026

Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis.

Lung cancer (Amsterdam, Netherlands)·2026

Targeting KIT and PDGFRA mutations in advanced gist: current and future clinical implications.

Expert review of anticancer therapy·2026

Biomaterial-Based Controlled Release Systems for Spinal Cord Remyelination.

Advanced materials (Deerfield Beach, Fla.)·2026

Molecular mechanism of Xanthotoxol against gastric cancer: A comprehensive study integrating network pharmacology, computer simulations, and experimental validation.

Animal models and experimental medicine·2026

ZNF865 (BLST) a Novel Regulator of DNA Damage and Cell Senescence in Back Pain.

Aging cell·2026

Contributions of the anion exchangers SLC26A1, SLC26A2, SLC26A3, and SLC26A6 to intestinal oxalate transport in human Caco2-BBE cells.

Physiological reports·2026

[Chinese expert consensus on the management of corneal and ocular surface adverse events related to antibody-drug conjugates (2026)].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us